Piperazine-derived lipid nanoparticles deliver mRNA to immune cells in vivo

• Published in: Nature communications Vol. 13; no. 1; p. 4766
• Main Authors: Ni, Huanzhen, Hatit, Marine Z. C., Zhao, Kun, Loughrey, David, Lokugamage, Melissa P., Peck, Hannah E., Cid, Ada Del, Muralidharan, Abinaya, Kim, YongTae, Santangelo, Philip J., Dahlman, James E.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 15.08.2022; Nature Publishing Group; Nature Portfolio
• Subjects: 42; 42/109; 42/62; 49; 631/45/147; 631/61/2300; 631/61/350/354; 631/61/391; 639/925/926/1051; Antibodies; Antigen-presenting cells; Antigens; Aptamers; Cellular structure; Deoxyribonucleic acid; DNA; Gene sequencing; Genetic modification; Genome editing; Hepatocytes; Humanities and Social Sciences; Immune system; In vivo methods and tests; Ligands; Lipid structure; Lipids; mRNA; multidisciplinary; Nanoparticles; Peptides; Piperazine; Ribonucleic acid; RNA; Science; Science (multidisciplinary); Tropism

In humans, lipid nanoparticles (LNPs) have safely delivered therapeutic RNA to hepatocytes after systemic administration and to antigen-presenting cells after intramuscular injection. However, systemic RNA delivery to non-hepatocytes remains challenging, especially without targeting ligands such as...